These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 22005114

  • 1. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [Abstract] [Full Text] [Related]

  • 2. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M.
    Hell J Nucl Med; 2023 Oct; 26 Suppl():19-20. PubMed ID: 37658556
    [Abstract] [Full Text] [Related]

  • 3. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
    Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ.
    Acta Oncol; 2007 Oct; 46(6):723-34. PubMed ID: 17653893
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [Abstract] [Full Text] [Related]

  • 5. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA, Papadogias D, Makras P, Grossman AB.
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [Abstract] [Full Text] [Related]

  • 6. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ, de Herder WW, Krenning EP.
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [Abstract] [Full Text] [Related]

  • 7. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K, Eriksson B.
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [Abstract] [Full Text] [Related]

  • 8. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Bal CS, Gupta SK, Zaknun JJ.
    Trop Gastroenterol; 2010 Jun; 31(2):87-95. PubMed ID: 20862981
    [Abstract] [Full Text] [Related]

  • 9. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP.
    Acc Chem Res; 2009 Jul 21; 42(7):873-80. PubMed ID: 19445476
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.
    Semin Nucl Med; 2002 Apr 21; 32(2):133-40. PubMed ID: 11965608
    [Abstract] [Full Text] [Related]

  • 11. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP.
    J Nucl Med; 2005 Jan 21; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [Abstract] [Full Text] [Related]

  • 12. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
    Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP.
    Eur J Nucl Med Mol Imaging; 2003 Mar 21; 30(3):417-22. PubMed ID: 12634971
    [Abstract] [Full Text] [Related]

  • 13. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
    Chiti A, van Graafeiland BJ, Savelli G, Ferrari L, Seregni E, Castellani MR, Bombardieri E.
    Ital J Gastroenterol Hepatol; 1999 Oct 21; 31 Suppl 2():S190-4. PubMed ID: 10604128
    [Abstract] [Full Text] [Related]

  • 14. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
    Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC.
    J Nucl Med; 2005 Jan 21; 46 Suppl 1():76S-82S. PubMed ID: 15653655
    [Abstract] [Full Text] [Related]

  • 15. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A, Łowczak A, Maciejkiewicz KM, Ćwikła JB.
    Nucl Med Rev Cent East Eur; 2018 Jan 21; 21(2):. PubMed ID: 29741203
    [Abstract] [Full Text] [Related]

  • 16. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ.
    Eur J Nucl Med Mol Imaging; 2012 Feb 21; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [Abstract] [Full Text] [Related]

  • 17. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.
    Chalkia MT, Stefanoyiannis AP, Chatziioannou SN, Round WH, Efstathopoulos EP, Nikiforidis GC.
    Australas Phys Eng Sci Med; 2015 Mar 21; 38(1):7-22. PubMed ID: 25427548
    [Abstract] [Full Text] [Related]

  • 18. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ.
    Best Pract Res Clin Gastroenterol; 2012 Dec 21; 26(6):867-81. PubMed ID: 23582925
    [Abstract] [Full Text] [Related]

  • 19. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP.
    Semin Nucl Med; 2010 Mar 21; 40(2):78-88. PubMed ID: 20113677
    [Abstract] [Full Text] [Related]

  • 20. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.
    Eur J Nucl Med Mol Imaging; 2005 Nov 21; 32(11):1288-95. PubMed ID: 16021448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.